Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options
October 6th 2018Narrowing in on neuroendocrine skin cancer, a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, took an in-depth look at prognostics and treatment options for Merkel cell carcinoma in the United States.
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 6th 2018During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 5th 2018During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists discussed the benefits of integrative oncology and nutrition for patients with neuroendocrine tumors.
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 5th 2018An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 5th 2018Two studies presented at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington assessed different tools for determining quality of life among patients with neuroendocrine tumors (NETs).
Collaborative, Multidisciplinary Care Has Positive Impact on Viral Suppression in HIV
October 3rd 2018Two studies presented at the 2018 Infectious Disease Week conference held in San Francisco, California, add to a pile of research demonstrating the positive impact of collaborative, multidisciplinary care in the HIV population, specifically on viral suppression.
Unstable Housing Has Adverse Impact on Viral Suppression, CD4 Cell Count in HIV Population
September 24th 2018Unstable housing among the HIV population is associated with decreased probability of viral suppression and adequate CD4 cell count. It also lowers the likelihood of mental health/counseling, visiting a healthcare provider, and engaging in continuity of care.
Researchers Tout Behavioral Science to Increase Physical Activity in Patients With MS
September 21st 2018Noting a disconnect between evidence of benefit and uptake of exercise in patients with multiple sclerosis (MS), researchers offer behavioral science, specifically Social Cognitive Theory, as an approach to increasing participation.
Bipartisan Group of Senators Drafts Legislation to End Surprise Medical Bills
September 21st 2018Senators Bill Cassidy, MD, R-Louisiana; Michael Bennet, D-Colorado; Chuck Grassley, R-Iowa; Tom Carper, D-Delaware; Todd Young, R-Indiana; and Clair McCaskill, D-Montana, have released the Protecting Patients from Surprise Medical Bills Act to protect patients from balanced billing for treatment and services from an out-of-network provider in an in-network facility.
More Than 25% of HIV Providers Don't Know If Their State Expanded Medicaid
September 20th 2018A survey has revealed gaps in HIV providers’ knowledge of the Affordable Care Act. However, despite these gaps, the majority of surveyed providers expressed belief that Medicaid expansion would improve both HIV outcomes and general outcomes for patients with the disease.
Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period
September 19th 2018With general consensus that those 70 years and older should not be routinely screened for prostate cancer, researchers argue that their study results identify an area for cutting low-value services to reduce healthcare spending.
Launch of Highly Efficacious HIV, Tuberculosis, and Malaria Vaccines Unlikely, Study Says
September 18th 2018Researchers determined that the current drug pipeline is unlikely to produce any highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.
Survey: Women Lack Confidence in Insurers, Employers to Meet the Needs of People With Migraine
September 17th 2018The survey of more than 340 women revealed an overwhelming belief that people with migraine are dismissed as exaggerating their symptoms and that employers don't understand the burden of migraine on their employees.
NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care
September 16th 2018A National Comprehensive Cancer Network (NCCN) working group dedicated to analyzing current challenges under existing policy and treatment paradigms presented their findings and recommendations at an NCCN Policy Summit in Washington, DC.
Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?
September 15th 2018As the term “value” has become a norm in healthcare, specifically in oncology, panelists at a National Comprehensive Cancer Network policy summit offered perspectives on where we are now in delivering high-quality cancer care under value-based payment models.
Prevalence of Acute Medication Use, Overuse, and Discontinuation Among Patients With Migraine
September 11th 2018Two studies presented at the PAINWeek conference in Las Vegas, Nevada, took a look into the prevalence of acute medication use and overuse among migraineurs, as well as rates of medication discontinuation due to lack of efficacy or side effects.
electroCore Unveils New Version of Noninvasive Vagus Nerve Stimulator for Migraine Pain
September 8th 2018GammaCore Sapphire, the newest version of gammaCore—a noninvasive vagus nerve stimulator—is now available in the United States to treat patients with migraine and episodic cluster headache.